Blurred symmetry in Q1 fund performance figures
By , 5 Apr 16
What a difference a year makes. In the first quarter of 2015, the top 10 funds were a mixture of Japanese equities, Russian equities, and biotechnology funds, with a frontier markets fund rounding things out.
Biotechnology
While perhaps not quite as one-dimensional, the bottom of the table was also dominated by a single theme – Biotechnology.
After doing very well for much of 2015, biotechnology funds had the wind taken out of their sails in the first three months of 2016.
The worst hit was the Candriam Biotechnology Fund, which fell 24% over the quarter, but all four biotech stocks that made the list were hard hit.
